SK Bioscience-Sanofi Pasteur on the verge of entering second clinical trial in the U.S.
SK Bioscience-Sanofi Pasteur on the verge of entering second clinical trial in the U.S.
  • Jung So-yeon
  • 승인 2020.03.31 10:48
  • 댓글 0
이 기사를 공유합니다

Submit an investigational new drug (IND) application to FDA for next-generation pneumococcal vaccine
Andong Lhouse, a vaccine plant of SK Bioscience, which can produce most of the vaccines available in Korea, including next-generation pneumococcal vaccines. (Courtesy of SK Bioscience)

SK Bioscience announced on March 30 that it has submitted an investigational new drug (IND) application to the FDA (Food and Drug Safety Agency) for its second clinical trial of next-generation pneumococcal vaccine being developed jointly with Sanofi Pasteur after completing its first trial in the U.S.

SK Chemicals, the parent company of SK Bioscience, signed a contract with Sanofi Pasteur, a global vaccine company, in 2014 to jointly develop and sell next-generation pneumococcal vaccine with the aim of making inroads into the global market.

Since then, the company has begun full-scale research and development and received $11 million for Milestone (per-stage technology fee) for successfully completing the first trial at the end of last year.

According to global market research firm Allied Market Research, the global sales of pneumococcal vaccine reached about $6.3 billion (7.6 trillion won). The market is expected to grow to $9 billion by 2025.

"The vaccine that will generate high value added in the global market has been developed with domestic technology. And we are gradually approaching success. Although second and third trials still remain, we will achieve the target by making best efforts," said Ahn Jae-yong, CEO of SK Bioscience.

Meanwhile, SK Bioscience, a newly established bio and vaccine company that has been spun off from SK Chemicals, is making full-fledged inroads into the global market through its own vaccine.

Recently, it has also started to secure technology for a vaccine development platform that can respond more quickly to the newly popular strains of viruses such as new corona, MERS and SARS.

SK Bioscience has a system that enables mass production as soon as the development of new vaccines is completed through Andong L House, a vaccine factory that boasts the world's highest level of facilities.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.